2.04
0.27 (15.25%)
| Penutupan Terdahulu | 1.77 |
| Buka | 1.85 |
| Jumlah Dagangan | 205,534 |
| Purata Dagangan (3B) | 75,636 |
| Modal Pasaran | 3,602,542 |
| Harga / Jualan (P/S) | 2.98 |
| Harga / Buku (P/B) | 0.560 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -2,151.43% |
| EPS Cair (TTM) | -5.05 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -79.00% |
| Nisbah Semasa (MRQ) | 1.70 |
| Aliran Tunai Operasi (OCF TTM) | -4.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.00 M |
| Pulangan Atas Aset (ROA TTM) | -100.63% |
| Pulangan Atas Ekuiti (ROE TTM) | -218.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Tivic Health Systems, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -4.0 |
| Purata | -0.25 |
|
Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body’s own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.81% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2025 | Pengumuman | Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome |
| 14 Nov 2025 | Pengumuman | Tivic Reports Third Quarter 2025 Financial Results |
| 13 Nov 2025 | Pengumuman | Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) |
| 10 Nov 2025 | Pengumuman | Tivic Expands Intellectual Property Portfolio |
| 06 Nov 2025 | Pengumuman | Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast |
| 22 Oct 2025 | Pengumuman | Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23 |
| 22 Sep 2025 | Pengumuman | Tivic Health CEO Jennifer Ernst to Present at Emerging Growth’s September Virtual Conference |
| 10 Sep 2025 | Pengumuman | Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |